Esperion Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.32
- Today's High:
- $1.39
- Open Price:
- $1.35
- 52W Low:
- $1.12
- 52W High:
- $8.87
- Prev. Close:
- $1.33
- Volume:
- 3356119
Company Statistics
- Market Cap.:
- $127.86 million
- Book Value:
- -3.779
- Revenue TTM:
- $80.97 million
- Operating Margin TTM:
- -228.63%
- Gross Profit TTM:
- $-70419000
- Profit Margin:
- -294.74%
- Return on Assets TTM:
- -38.91%
- Return on Equity TTM:
- -260.79%
Company Profile
Esperion Therapeutics Inc had its IPO on 2013-06-26 under the ticker symbol ESPR.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Esperion Therapeutics Inc has a staff strength of 199 employees.
Stock update
Shares of Esperion Therapeutics Inc opened at $1.35 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.32 - $1.39, and closed at $1.34.
This is a +0.75% increase from the previous day's closing price.
A total volume of 3,356,119 shares were traded at the close of the day’s session.
In the last one week, shares of Esperion Therapeutics Inc have slipped by -14.1%.
Esperion Therapeutics Inc's Key Ratios
Esperion Therapeutics Inc has a market cap of $127.86 million, indicating a price to book ratio of 98.4236 and a price to sales ratio of 5.982.
In the last 12-months Esperion Therapeutics Inc’s revenue was $80.97 million with a gross profit of $-70419000 and an EBITDA of $-184688992. The EBITDA ratio measures Esperion Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Esperion Therapeutics Inc’s operating margin was -228.63% while its return on assets stood at -38.91% with a return of equity of -260.79%.
In Q1, Esperion Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 29.2%.
Esperion Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -4.78
Its diluted EPS in the last 12-months stands at $-3.28 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -4.78. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Esperion Therapeutics Inc’s profitability.
Esperion Therapeutics Inc stock is trading at a EV to sales ratio of 6.935 and a EV to EBITDA ratio of -2.6749. Its price to sales ratio in the trailing 12-months stood at 5.982.
Esperion Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $251.82 million
- Total Liabilities
- $95.49 million
- Operating Cash Flow
- $25.00 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Esperion Therapeutics Inc ended 2024 with $251.82 million in total assets and $0 in total liabilities. Its intangible assets were valued at $251.82 million while shareholder equity stood at $-1401755000.00.
Esperion Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $95.49 million in other current liabilities, 87000.00 in common stock, $-1401755000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $144.91 million and cash and short-term investments were $162.34 million. The company’s total short-term debt was $305,000 while long-term debt stood at $260.32 million.
Esperion Therapeutics Inc’s total current assets stands at $250.61 million while long-term investments were $0 and short-term investments were $17.43 million. Its net receivables were $36.42 million compared to accounts payable of $17.07 million and inventory worth $39.35 million.
In 2024, Esperion Therapeutics Inc's operating cash flow was $25.00 million while its capital expenditure stood at $0.
Comparatively, Esperion Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.34
- 52-Week High
- $8.87
- 52-Week Low
- $1.12
- Analyst Target Price
- $10.19
Esperion Therapeutics Inc stock is currently trading at $1.34 per share. It touched a 52-week high of $8.87 and a 52-week low of $8.87. Analysts tracking the stock have a 12-month average target price of $10.19.
Its 50-day moving average was $1.53 and 200-day moving average was $3.23 The short ratio stood at 7.09 indicating a short percent outstanding of 0%.
Around 45.3% of the company’s stock are held by insiders while 9736.2% are held by institutions.
Frequently Asked Questions About Esperion Therapeutics Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.